BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Head and Neck Cancer

Interventions: Biological: Urelumab
Biological: Cetuximab

First Posted Date: 2014-04-10

Last Posted Date: 2017-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 66

Registration Number: NCT02110082

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Upmc Cancer Center, Pittsburgh, Pennsylvania, United States

and more 4 locations

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV 3DAA FDC
Drug: BMS-791325

First Posted Date: 2014-04-09

Last Posted Date: 2014-07-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT02108639

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States

and more 1 locations

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Nivolumab
Drug: Cetuximab
Drug: Methotrexate
Drug: Docetaxel

First Posted Date: 2014-04-07

Last Posted Date: 2022-10-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 361

Registration Number: NCT02105636

Locations: 🇨🇳
Local Institution - 0064, Taipei, Taiwan
🇨🇭
Local Institution - 0051, Zuerich, Switzerland
🇺🇸
Local Institution - 0004, Metairie, Louisiana, United States

and more 44 locations

Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: FDC of Daclatasvir, Asunaprevir and BMS-791325
Drug: FDC of Norethindrone and Ethinyl Estradiol
Drug: BMS-791325

First Posted Date: 2014-04-04

Last Posted Date: 2014-08-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT02103569

Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir, Asunaprevir and BMS-791325 FDC
Drug: BMS-791325
Drug: Rosuvastatin

First Posted Date: 2014-04-04

Last Posted Date: 2014-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT02104843

Bioavailability of Apixaban Crushed Tablet

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: Apixaban

First Posted Date: 2014-04-01

Last Posted Date: 2016-03-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT02101112

Drug Interaction Study With Rosuvastatin

Phase 1

Completed

Conditions: Immunosuppression For Disease

Interventions: Drug: BMS-986020
Drug: Rosuvastatin

First Posted Date: 2014-04-01

Last Posted Date: 2014-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 26

Registration Number: NCT02101125

Locations: 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Conditions: Chronic Hepatitis C

First Posted Date: 2014-03-27

Last Posted Date: 2016-01-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02097966

Locations: 🇬🇧
Local Institution, Wrexham, United Kingdom
🇬🇧
Local Instituition, Liverpool, Merseyside, United Kingdom

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Biological: BMS-986036
Biological: Placebo (Matching with BMS-986036)

First Posted Date: 2014-03-27

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 219

Registration Number: NCT02097277

Locations: 🇨🇦
Recherche Gcp Research, Montreal, Quebec, Canada
🇺🇸
Arkansas Clinical Research, Little Rock, Arkansas, United States
🇺🇸
Premier Research, Trenton, New Jersey, United States

and more 12 locations

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV 3DAA FDC

First Posted Date: 2014-03-26

Last Posted Date: 2014-10-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT02095860

Locations: 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy